

Food and Drug Administration

Antiviral Drugs Advisory Committee

March 11, 2005

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Information

Bristol-Myers Squibb Company

New drug applications 21-797 and 21-798, entecavir tablets and entecavir oral solution, respectively, Bristol-Myers Squibb Co., proposed for the treatment of patients with chronic hepatitis B infection (HBV).

[Bristol-Myers Squibb Company Background Information](#)

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552).

These redacted portions will appear as white space on the screen or on the printed page.

Background Information

[\[Word\]](#) [\[PDF\]](#) [\[HTML\]](#)